Company
Every investor coverage indicates participated in a round Fibrotech Therapeutics raised.
Investors whose own portfolio pages list Fibrotech Therapeutics, even though we haven't found any coverage of the round yet.
| Investor | Listed on |
|---|---|
| Brandon Capital | its portfolio page ↗ |
The transaction that ended Fibrotech Therapeutics's run as a startup, per published coverage. It closes the funding history too, where it is the ladder's last rung.
| Bought by | Kind | Announced | Price | Sources |
|---|---|---|---|---|
| Shire plc | Acquisition | 2014 | US$75m (A$85.6m) | Startup Daily, anthillonline.com |
Companies Fibrotech Therapeutics acquired or merged with, per published coverage. Buying a company is not investing in one: nothing here counts in the deals column.
Stories naming Fibrotech Therapeutics. Where several outlets covered the same round, they are bundled under whichever ran the fullest account.
Uniseed adds Monash and a four-university NSW collaboration, lifting its third fund by $6.75 million to $56.75 million; the article recalls past portfolio sales to Novartis, Shire and Schneider Electric.
Venture fund Uniseed led a million-dollar slice of probiotic drinks maker PERKii's four-million-dollar round, its first deal from its new $50 million fund, to fund a national launch.
Also Startup Daily
Fibrotech Therapeutics raised $3 million in Series A backing from Brandon Capital-managed funds MRCF, BBF1 IIF and Uniseed to advance fibrosis drug FT011 through Phase Ib trials.